Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 5/20 | 0.62 |
| ▸ | JAK1 | P23458 | 4/20 | 0.62 |
| ▸ | JAK2 | O60674 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.62 |
| ▸ | IL2 | P60568 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.46 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886125 | 0.85 | IL2 (0.52) | TYK2JAK1JAK2HTTNOD2 | |
| SCHEMBL987314 | 0.85 | JAK2 (0.62) | TYK2JAK1JAK2HTTNOD2 | |
| SCHEMBL8193723 | 0.85 | TYK2 (0.62) | TYK2JAK1JAK2HTTNOD2 | |
| SCHEMBL15456644 | 0.83 | IL2 (0.67) | TYK2JAK1JAK2HTTNOD2 | |
| SCHEMBL8227240 | 0.82 | JAK2 (0.58) | TYK2JAK1JAK2HTTNOD2 | |
| SCHEMBL1825939 | 0.81 | IL2 (0.76) | TYK2JAK1JAK2HTTNOD2 | |
| SCHEMBL10101287 | 0.78 | JAK2 (0.53) | TYK2JAK1JAK2HTTNOD2 | |
| SCHEMBL13067923 | 0.78 | TYK2 (0.48) | TYK2JAK1JAK2HTTNOD2 | |
| SCHEMBL8124406 | 0.78 | TYK2 (1.00) | TYK2JAK1JAK2HTTNOD2 | |
| SCHEMBL12988970 | 0.78 | IL2 (0.71) | TYK2JAK1JAK2HTTNOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349841-B2 | Vinyl-aryl derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349841-B2 | Vinyl-aryl derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120040997-A9 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20120040997-A9 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20100292252-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-18 | — | — | US | disclosed |
| US-20100292252-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040997-A9 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | MALT1, VCAM1, TSLP | TYK2 317/4885JAK1 1331/4885JAK2 771/4885 |
| US-20100292252-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | MALT1, VCAM1, TSLP | TYK2 317/4885JAK1 1331/4885JAK2 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.